Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297002146> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4297002146 endingPage "58" @default.
- W4297002146 startingPage "52" @default.
- W4297002146 abstract "Abstract Background Information is lacking from real‐life studies evaluating the efficacy of tildrakizumab in moderate‐to‐severe psoriasis. Materials and Methods We retrospectively analysed a database of 30 patients with moderate‐to‐severe psoriasis (PsO) that were treated with tildrakizumab (100 mg, s.c.) and followed for 36 weeks. Clinical efficacy (disease severity and treatment response) was evaluated by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, and 36 weeks. The quality of life (QoL) of PsO patients was measured using the Dermatology Life Quality Index (DLQI). Results A PASI score of <3 was achieved after 12, 24, and 36 weeks in 86.7%, 100%, and 100% patients, respectively (aged 46.3 ± 13.3 years) treated with tildrakizumab. PASI score significantly decreased from 17.6 ± 4.7 at baseline to 4.7 ± 4.7 and 1.1 ± 3.9 at 4 and 12 weeks remaining <1 up to 36 weeks ( p < 0.001 vs. baseline), and PASI −75–90 and −100 response was achieved in 100%, 96.7%, and 60% of patients respectively at 36 weeks. DLQI also significantly decreased from baseline (13.8 ± 2.9) to 3.6 ± 1.6 at 4 weeks, 1.4 ± 0.6 at 12 weeks and 0 at Week 24 and 36 ( p < 0.001 vs. baseline). Multivariate regression revealed that the effect of tildrakizumab on PASI score or DLQI at 4 weeks was independent from the predictor variables age, gender, BMI, disease duration, previous biologic, or presence of comorbidities. No adverse event was reported during treatment with tildrakizumab. Conclusion This retrospective study shows that patients with moderate‐to‐severe PsO treated with tildrakizumab in the real world‐setting was effective and safe up to 36 weeks." @default.
- W4297002146 created "2022-09-25" @default.
- W4297002146 creator A5024541637 @default.
- W4297002146 creator A5067507876 @default.
- W4297002146 creator A5070566832 @default.
- W4297002146 creator A5072653864 @default.
- W4297002146 creator A5074398260 @default.
- W4297002146 creator A5077189043 @default.
- W4297002146 date "2022-09-23" @default.
- W4297002146 modified "2023-09-26" @default.
- W4297002146 title "Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting" @default.
- W4297002146 cites W1994127723 @default.
- W4297002146 cites W2063627867 @default.
- W4297002146 cites W2097170399 @default.
- W4297002146 cites W2271643717 @default.
- W4297002146 cites W2593291425 @default.
- W4297002146 cites W2623888527 @default.
- W4297002146 cites W2953295625 @default.
- W4297002146 cites W2954786324 @default.
- W4297002146 cites W2999032467 @default.
- W4297002146 cites W3045091446 @default.
- W4297002146 cites W3129022701 @default.
- W4297002146 cites W3162925909 @default.
- W4297002146 cites W3169153889 @default.
- W4297002146 cites W3203757825 @default.
- W4297002146 cites W3205535255 @default.
- W4297002146 cites W3206647100 @default.
- W4297002146 cites W3213975960 @default.
- W4297002146 cites W3214846418 @default.
- W4297002146 cites W4223474344 @default.
- W4297002146 cites W4229335492 @default.
- W4297002146 doi "https://doi.org/10.1002/jvc2.65" @default.
- W4297002146 hasPublicationYear "2022" @default.
- W4297002146 type Work @default.
- W4297002146 citedByCount "0" @default.
- W4297002146 crossrefType "journal-article" @default.
- W4297002146 hasAuthorship W4297002146A5024541637 @default.
- W4297002146 hasAuthorship W4297002146A5067507876 @default.
- W4297002146 hasAuthorship W4297002146A5070566832 @default.
- W4297002146 hasAuthorship W4297002146A5072653864 @default.
- W4297002146 hasAuthorship W4297002146A5074398260 @default.
- W4297002146 hasAuthorship W4297002146A5077189043 @default.
- W4297002146 hasBestOaLocation W42970021461 @default.
- W4297002146 hasConcept C126322002 @default.
- W4297002146 hasConcept C159110408 @default.
- W4297002146 hasConcept C16005928 @default.
- W4297002146 hasConcept C2776173921 @default.
- W4297002146 hasConcept C2777011040 @default.
- W4297002146 hasConcept C2779951463 @default.
- W4297002146 hasConcept C2780564577 @default.
- W4297002146 hasConcept C30036603 @default.
- W4297002146 hasConcept C3020604521 @default.
- W4297002146 hasConcept C71924100 @default.
- W4297002146 hasConcept C90924648 @default.
- W4297002146 hasConceptScore W4297002146C126322002 @default.
- W4297002146 hasConceptScore W4297002146C159110408 @default.
- W4297002146 hasConceptScore W4297002146C16005928 @default.
- W4297002146 hasConceptScore W4297002146C2776173921 @default.
- W4297002146 hasConceptScore W4297002146C2777011040 @default.
- W4297002146 hasConceptScore W4297002146C2779951463 @default.
- W4297002146 hasConceptScore W4297002146C2780564577 @default.
- W4297002146 hasConceptScore W4297002146C30036603 @default.
- W4297002146 hasConceptScore W4297002146C3020604521 @default.
- W4297002146 hasConceptScore W4297002146C71924100 @default.
- W4297002146 hasConceptScore W4297002146C90924648 @default.
- W4297002146 hasIssue "1" @default.
- W4297002146 hasLocation W42970021461 @default.
- W4297002146 hasOpenAccess W4297002146 @default.
- W4297002146 hasPrimaryLocation W42970021461 @default.
- W4297002146 hasRelatedWork W1978428707 @default.
- W4297002146 hasRelatedWork W2028656318 @default.
- W4297002146 hasRelatedWork W2461170543 @default.
- W4297002146 hasRelatedWork W2462324581 @default.
- W4297002146 hasRelatedWork W2545526290 @default.
- W4297002146 hasRelatedWork W2998923669 @default.
- W4297002146 hasRelatedWork W4213143336 @default.
- W4297002146 hasRelatedWork W4247679967 @default.
- W4297002146 hasRelatedWork W4255680485 @default.
- W4297002146 hasRelatedWork W4320521215 @default.
- W4297002146 hasVolume "2" @default.
- W4297002146 isParatext "false" @default.
- W4297002146 isRetracted "false" @default.
- W4297002146 workType "article" @default.